Abstract
Pancreatic ductal adenocarcinoma has been long count to one of the most severe diagnosis in solid oncology. Increasing incidence and persistently high mortality lead to intensive research into this highly malignant disease.
Chemotherapy, in specific cases supplemented with radiotherapy, is still the most effective treatment modality. The use of targeted therapy is also limited.
As with other cancers, great hopes are placed in the renaissance of immunotherapy. The following article aims to provide a brief summary of the knowledge so far gained on the treatment of patients with PDAC by modulating the immune system and outlining new possibilities and current trends.